Zhaohui Su is a Research Scientist at the Center for Biostatistics in AIDS Research (CBAR) and the Department of Biostatistics at Harvard University. His research interests include design of clinical trials, longitudinal data analysis and suvival data analysis.

• 1. Rosenberg MS, Garratt KA, Su Z, and Bowden RL, Meta-analysis in Plant Pathology: Synthesizing Research Results, Symposium: New Application of Statistical Tools in Plant Pathology, 94 (9), 1013 - 17, 2004.
• 2. Su Z, Yang S. A Note on Lack-of-Fit Tests for Linear Models without Replication, JASA, Vol 101 (473), 205 - 210, 2006
• 3. Bockus WW, Su Z, Garrett KA, Gill BS, Stack JP, Bowden RL, Fritz AK, Roozeboom KL, Martin TJ. Number of experiments needed to determine wheat disease phenotypes for four wheat diseases, Plant Disease, 107(1), 2007; 103-108.
• 4. Hopper JW, Su Z, Looby AR, Ryan ET, Penetar DM, Palmer CM, Lukas SE. Incidence and patterns of polydrug use and craving for ecstasy in regular ecstasy users: An ecological momentary assessment study. Drug Alcohol Depend, 85 (2006); 221-235.
• 5. Penetar DM, Looby AR, Su Z, Lundahl LH, Erös-Sarnyai M, McNeil JF, Lukas SE. Benztropine pretreatment does not affect responses to acute cocaine administration In human volunteers. Human Psychopharmacology. 2006 Dec;21(8):549-59.
• 6. Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, Peterson T, Krambrink A, Jahed N, McMahon D, Margolis DM, and the A5170 study team. Antiretroviral treatment interruption in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: A prospective study: Results of ACTG 5170. Journal of Infectious Disease, 195: 1426-1436, 2007.
• 7. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik FR, Timpone J, Rodriguez B, Gulick RM. Chemokine Coreceptor Tropism among Antiretroviral-Experienced Patients Screening for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group 5211. Clinical Infectious Diseases, volume 44 (2007), 591-595.
• 8. Gulick R, Su Z, Flexner C, Hughes M, Skolnik P, Godfrey C, Greaves W, Wilkin T, Gross R, Coakley E, Zolopa A, Hirsch M, Kuritzkes D, Phase II study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-infected treatment-experienced subjects: ACTG 5211. Journal of Infectious Disease, 196(2), 304-12, 2007.
• 9. Robertson K, Su Z, Margolis D, Krambrink A, Havlir D, Evans S, and Skiest D, for the A5170 study team, Neurocognitive function before and after antiretroviral treatment discontinuation in patients with immunological preservation: Neurological Sub-study of ACTG 5170, submitted.
• 10. Garrett K, Zúñiga L, Roncal E, Forbes G, Mundt C, Su Z, and Nelson R, the Effects of Host Biodiversity on Disease Levels across a Climatic Gradient. Submitted.
• 11. Bradley H, Mellors J, Krambrink A, Su Z, Skiest D, Margolis D, Patel S, Barnas D, Coombs R, Aweeka F, Morse G, Haas D, Kim R, Boltz V, Palmer S, Coffin J, Havlir D, Selection of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistant HIV-1 After Discontinuation of a Virologically Suppressive Regimen. Submitted.
• 12. Vahey M, Wang Z, Ockenhouse C, Su Z, Nau M, Krambrink A, Skiest D, and Margolis D, Differential Expression of Genes Associated with the Regulation of Apoptosis Predicts Progression in Persons Who Discontinue Antiretroviral Therapy, submitted.